{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:59:00Z","timestamp":1722023940804},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00292-019-00688-5","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:17:21Z","timestamp":1573226241000},"page":"331-338","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapiepr\u00e4diktive Biomarker des Harnblasenkarzinoms"],"prefix":"10.1007","volume":"40","author":[{"given":"H.","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"688_CR1","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-07-0109","volume":"13","author":"AB Als","year":"2007","unstructured":"Als\u00a0AB, Dyrskjot\u00a0L, Von Der Maase\u00a0H et al (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13:4407\u20134414","journal-title":"Clin Cancer Res"},{"key":"688_CR2","series-title":"AWMF-Registrierungsnummer 032\/038OL","first-page":"49","volume-title":"S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1","author":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften","year":"2016","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2016) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1. AWMF-Registrierungsnummer 032\/038OL. AWMF, DKG, DKH, Berlin, S 49\u201352"},{"key":"688_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a\u00a0single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376","journal-title":"Lancet"},{"key":"688_CR4","volume-title":"Bericht zum Krebsgeschehen in Deutschland 2016","author":"B Barnes","year":"2017","unstructured":"Barnes\u00a0B, Bertz\u00a0J, Buttmann-Schweiger\u00a0N et al (2017) Bericht zum Krebsgeschehen in Deutschland 2016. RKI, Berlin"},{"key":"688_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00292-015-0129-5","volume":"37","author":"S Bertz","year":"2016","unstructured":"Bertz\u00a0S, Hartmann\u00a0A, Knuchel-Clarke\u00a0R et al (2016) Specific types of bladder cancer. Pathologe 37:40\u201351","journal-title":"Pathologe"},{"key":"688_CR6","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","volume":"11","author":"E Blaveri","year":"2005","unstructured":"Blaveri\u00a0E, Simko\u00a0JP, Korkola\u00a0JE et\u00a0al (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11:4044\u20134055","journal-title":"Clin Cancer Res"},{"key":"688_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315\u2013322","journal-title":"Nature"},{"key":"688_CR8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers\u00a0ZR, Connelly\u00a0CF, Fabrizio\u00a0D et\u00a0al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34","journal-title":"Genome Med"},{"key":"688_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi\u00a0W, Porten\u00a0S, Kim\u00a0S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165","journal-title":"Cancer Cell"},{"key":"688_CR10","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1158\/0008-5472.CAN-10-1202","volume":"70","author":"A Choudhury","year":"2010","unstructured":"Choudhury\u00a0A, Nelson\u00a0LD, Teo\u00a0MT et al (2010) MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 70:7017\u20137026","journal-title":"Cancer Res"},{"key":"688_CR11","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer\u00a0JS, Hoadley\u00a0KA, Chism\u00a0DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S\u00a0A 111:3110\u20133115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"688_CR12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskjot","year":"2003","unstructured":"Dyrskjot\u00a0L, Thykjaer\u00a0T, Kruhoffer\u00a0M et\u00a0al (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33:90\u201396","journal-title":"Nat Genet"},{"key":"688_CR13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","volume":"69","author":"FH Groenendijk","year":"2016","unstructured":"Groenendijk\u00a0FH, De Jong\u00a0J, Van De Fransen Putte\u00a0EE et al (2016) ERBB2 mutations characterize a\u00a0subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69:384\u2013388","journal-title":"Eur Urol"},{"key":"688_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard\u00a0J, Lamy\u00a0P, Nordentoft\u00a0I et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27\u201342","journal-title":"Cancer Cell"},{"key":"688_CR15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.5250","volume":"248","author":"T Heide","year":"2019","unstructured":"Heide\u00a0T, Maurer\u00a0A, Eipel\u00a0M et\u00a0al (2019) Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. J\u00a0Pathol 248:230\u2013242","journal-title":"J Pathol"},{"key":"688_CR16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1593\/neo.10402","volume":"12","author":"AC Hoffmann","year":"2010","unstructured":"Hoffmann\u00a0AC, Wild\u00a0P, Leicht\u00a0C et\u00a0al (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12:628\u2013636","journal-title":"Neoplasia"},{"key":"688_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/488460","author":"A Kamoun","year":"2019","unstructured":"Kamoun\u00a0A, De Reyni\u00e8s\u00a0A, Allory\u00a0Y et al (2019) The consensus molecular classification of muscle-invasive bladder cancer. bioRxiv. \nhttps:\/\/doi.org\/10.1101\/488460","journal-title":"bioRxiv"},{"key":"688_CR18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"J Kim","year":"2019","unstructured":"Kim\u00a0J, Kwiatkowski\u00a0D, Mcconkey\u00a0DJ et\u00a0al (2019) The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a\u00a0subset of patients with high survival probability. Eur Urol 75:961\u2013964","journal-title":"Eur Urol"},{"key":"688_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.04.010","author":"P Kollberg","year":"2019","unstructured":"Kollberg\u00a0P, Chebil\u00a0G, Eriksson\u00a0P et al (2019) Molecular subtypes applied to a\u00a0population-based modern cystectomy series do not predict cancer-specific survival. Urol Oncol. \nhttps:\/\/doi.org\/10.1016\/j.urolonc.2019.04.010","journal-title":"Urol Oncol"},{"key":"688_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.04.015","author":"U Krafft","year":"2019","unstructured":"Krafft\u00a0U, Tschirdewahn\u00a0S, Hess\u00a0J et\u00a0al (2019) Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urol Oncol. \nhttps:\/\/doi.org\/10.1016\/j.urolonc.2019.04.015","journal-title":"Urol Oncol"},{"key":"688_CR21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence\u00a0MS, Stojanov\u00a0P, Polak\u00a0P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214\u2013218","journal-title":"Nature"},{"key":"688_CR22","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","volume":"190","author":"BJ Linder","year":"2013","unstructured":"Linder\u00a0BJ, Boorjian\u00a0SA, Cheville\u00a0JC et al (2013) The impact of histological reclassification during pathology re-review\u2014evidence of a\u00a0Will Rogers effect in bladder cancer? J\u00a0Urol 190:1692\u20131696","journal-title":"J Urol"},{"key":"688_CR23","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","volume":"70","author":"D Lindgren","year":"2010","unstructured":"Lindgren\u00a0D, Frigyesi\u00a0A, Gudjonsson\u00a0S et\u00a0al (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463\u20133472","journal-title":"Cancer Res"},{"key":"688_CR24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu\u00a0D, Plimack\u00a0ER, Hoffman-Censits\u00a0J et al (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2:1094\u20131096","journal-title":"JAMA Oncol"},{"key":"688_CR25","doi-asserted-by":"crossref","first-page":"E2514","DOI":"10.3390\/ijms19092514","volume":"19","author":"I Lodewijk","year":"2018","unstructured":"Lodewijk\u00a0I, Duenas\u00a0M, Rubio\u00a0C et\u00a0al (2018) Liquid biopsy biomarkers in bladder cancer: a current need for patient diagnosis and monitoring. Int J Mol Sci 19:E2514","journal-title":"Int J Mol Sci"},{"key":"688_CR26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan\u00a0S, Turley\u00a0SJ, Nickles\u00a0D et al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548","journal-title":"Nature"},{"key":"688_CR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.urolonc.2010.04.008","volume":"28","author":"DJ McConkey","year":"2010","unstructured":"McConkey\u00a0DJ, Lee\u00a0S, Choi\u00a0W et\u00a0al (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 28:429\u2013440","journal-title":"Urol Oncol"},{"key":"688_CR28","volume-title":"Rote-Hand-Brief: Keytruda (Pembrolizumab): Einschr\u00e4nkung des Anwendungsgebiets \u201eZur Behandlung des lokal fortgeschrittenen oder metastasierenden Urothelkarzinoms bei Erwachsenen, die nicht f\u00fcr eine Cisplatin-basierte Therapie geeignet sind\u201c","author":"Paul-Ehrlich-Institut","year":"2018","unstructured":"Paul-Ehrlich-Institut (2018) Rote-Hand-Brief: Keytruda (Pembrolizumab): Einschr\u00e4nkung des Anwendungsgebiets \u201eZur Behandlung des lokal fortgeschrittenen oder metastasierenden Urothelkarzinoms bei Erwachsenen, die nicht f\u00fcr eine Cisplatin-basierte Therapie geeignet sind\u201c. \nhttps:\/\/www.pei.de\/DE\/arzneimittelsicherheit-vigilanz\/archivsicherheitsinformationen\/2018\/ablage2018\/2018-07-11-rhb-keytruda-pembrolizumab.html\n\n. Zugegriffen: 29. Jan. 2019"},{"key":"688_CR29","volume-title":"Rote-Hand-Brief: Tecentriq (Atezolizumab): Einschr\u00e4nkung der Indikation zur Behandlung des lokal fortgeschrittenen oder metastasierten Urothelkarzinoms bei erwachsenen Patienten, die f\u00fcr eine cisplatinbasierte Chemotherapie ungeeignet sind","author":"Paul-Ehrlich-Institut","year":"2018","unstructured":"Paul-Ehrlich-Institut (2018) Rote-Hand-Brief: Tecentriq (Atezolizumab): Einschr\u00e4nkung der Indikation zur Behandlung des lokal fortgeschrittenen oder metastasierten Urothelkarzinoms bei erwachsenen Patienten, die f\u00fcr eine cisplatinbasierte Chemotherapie ungeeignet sind. \nhttps:\/\/www.pei.de\/DE\/arzneimittelsicherheit-vigilanz\/archivsicherheitsinformationen\/2018\/ablage2018\/2018-07-09-rhb-tecentriq-atezolizumab.html\n\n. Zugegriffen: 29. Jan. 2019"},{"key":"688_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","volume":"75","author":"EJ Pietzak","year":"2019","unstructured":"Pietzak\u00a0EJ, Zabor\u00a0EC, Bagrodia\u00a0A et al (2019) Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a\u00a0basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol 75:231\u2013239","journal-title":"Eur Urol"},{"key":"688_CR31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack\u00a0ER, Dunbrack\u00a0RL, Brennan\u00a0TA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68:959\u2013967","journal-title":"Eur Urol"},{"key":"688_CR32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","volume":"43","author":"H Reis","year":"2019","unstructured":"Reis\u00a0H, Serrette\u00a0R, Posada\u00a0J et al (2019) PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 43:920\u2013927","journal-title":"Am J Surg Pathol"},{"key":"688_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00292-018-0498-7","volume":"39","author":"H Reis","year":"2018","unstructured":"Reis\u00a0H, Szarvas\u00a0T (2018) Urachal cancer\u2014current concepts of a\u00a0rare cancer (German version). Pathologe 39:291\u2013300","journal-title":"Pathologe"},{"key":"688_CR34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00292-019-0606-3","volume":"40","author":"H Reis","year":"2019","unstructured":"Reis\u00a0H, Szarvas\u00a0T, Grunwald\u00a0V (2019) Predictive biomarkers in oncologic uropathology. Pathologe 40:264\u2013275","journal-title":"Pathologe"},{"key":"688_CR35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson\u00a0AG, Kim\u00a0J, Al-Ahmadie\u00a0H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540\u2013556.e25","journal-title":"Cell"},{"key":"688_CR36","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg\u00a0JE, Hoffman-Censits\u00a0J, Powles\u00a0T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a\u00a0single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"},{"key":"688_CR37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","volume":"39","author":"HU Schildhaus","year":"2018","unstructured":"Schildhaus\u00a0HU (2018) Predictive value of PD-L1 diagnostics. Pathologe 39:498\u2013519","journal-title":"Pathologe"},{"key":"688_CR38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler\u00a0R, Al-Deen Ashab\u00a0H, Erho\u00a0N et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544\u2013554","journal-title":"Eur Urol"},{"key":"688_CR39","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","volume":"25","author":"R Seiler","year":"2018","unstructured":"Seiler\u00a0R, Gibb\u00a0EA, Wang\u00a0NQ et al (2018) Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin Cancer Res 25:5082\u20135093","journal-title":"Clin Cancer Res"},{"key":"688_CR40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma\u00a0P, Retz\u00a0M, Siefker-Radtke\u00a0A et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a\u00a0multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312\u2013322","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"688_CR41","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2018.36.15_suppl.4503","volume":"36","author":"A Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke\u00a0A, Necchi\u00a0A, Park\u00a0SH et al (2018) First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J\u00a0Clin Oncol 36(15 Suppl):4503","journal-title":"J Clin Oncol"},{"key":"688_CR42","doi-asserted-by":"crossref","first-page":"e2106","DOI":"10.1016\/S1569-9056(19)31526-X","volume":"18","author":"G Sjodahl","year":"2019","unstructured":"Sjodahl\u00a0G, Abrahamsson\u00a0J, Holmsten\u00a0K et al (2019) Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer. Eur Urol Suppl 18:e2106\u2013e2107","journal-title":"Eur Urol Suppl"},{"key":"688_CR43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sjodahl","year":"2017","unstructured":"Sjodahl\u00a0G, Eriksson\u00a0P, Liedberg\u00a0F et al (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J\u00a0Pathol 242:113\u2013125","journal-title":"J Pathol"},{"key":"688_CR44","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sjodahl","year":"2012","unstructured":"Sjodahl\u00a0G, Lauss\u00a0M, Lovgren\u00a0K et\u00a0al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18:3377\u20133386","journal-title":"Clin Cancer Res"},{"key":"688_CR45","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/cam4.1979","volume":"8","author":"H Su","year":"2019","unstructured":"Su\u00a0H, Jiang\u00a0H, Tao\u00a0T et\u00a0al (2019) Hope and challenge: precision medicine in bladder cancer. Cancer Med 8:1806\u20131816","journal-title":"Cancer Med"},{"key":"688_CR46","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/j.juro.2012.02.1867","volume":"187","author":"T Szarvas","year":"2012","unstructured":"Szarvas\u00a0T, Kramer\u00a0G, Hess\u00a0J et al (2012) Tissue mmp\u20117 expression predicts survival in bladder cancer patients treated with cisplatin-based chemotherapy. J\u00a0Urol 187:e575\u2013e575","journal-title":"J Urol"},{"key":"688_CR47","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.21037\/tcr.2019.01.05","volume":"8","author":"T Szarvas","year":"2019","unstructured":"Szarvas\u00a0T, Olah\u00a0C, Reis\u00a0H (2019) Neoadjuvant cisplatin-based chemotherapy in \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer\u2014Is it a\u00a0surrogate for molecular subtypes? Transl Cancer Res 8:S176\u2013S179","journal-title":"Transl Cancer Res"},{"key":"688_CR48","doi-asserted-by":"crossref","first-page":"E2568","DOI":"10.3390\/ijms19092568","volume":"19","author":"MP Tan","year":"2018","unstructured":"Tan\u00a0MP, Attard\u00a0G, Huddart\u00a0RA (2018) Circulating tumour DNA in muscle-invasive bladder cancer. Int J Mol Sci 19:E2568","journal-title":"Int J Mol Sci"},{"key":"688_CR49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2119\/molmed.2014.00250","volume":"21","author":"H Taubert","year":"2015","unstructured":"Taubert\u00a0H, Wach\u00a0S, Jung\u00a0R et al (2015) Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients. Mol Med 21:371\u2013380","journal-title":"Mol Med"},{"key":"688_CR50","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","volume":"23","author":"MY Teo","year":"2017","unstructured":"Teo\u00a0MY, Bambury\u00a0RM, Zabor\u00a0EC et al (2017) DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 23:3610\u20133618","journal-title":"Clin Cancer Res"},{"key":"688_CR51","doi-asserted-by":"crossref","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","volume":"7","author":"MBH Thomsen","year":"2017","unstructured":"Thomsen\u00a0MBH, Nordentoft\u00a0I, Lamy\u00a0P et\u00a0al (2017) Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep 7:11702","journal-title":"Sci Rep"},{"key":"688_CR52","volume-title":"FDA approves first targeted therapy for metastatic bladder cancer","author":"A Turney","year":"2019","unstructured":"Turney\u00a0A (2019) FDA approves first targeted therapy for metastatic bladder cancer. \nhttps:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm635906.htm\n\n. Zugegriffen: 29. Jan. 2019"},{"key":"688_CR53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2018.06.019","volume":"74","author":"AM Udager","year":"2018","unstructured":"Udager\u00a0AM, McDaniel\u00a0AS, Hovelson\u00a0DH et al (2018) Frequent PD-L1 protein expression and molecular correlates in urinary bladder squamous cell carcinoma. Eur Urol 74:529\u2013531","journal-title":"Eur Urol"},{"key":"688_CR54","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen\u00a0EM, Mouw\u00a0KW, Kim\u00a0P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140\u20131153","journal-title":"Cancer Discov"},{"key":"688_CR55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","volume":"75","author":"JI Warrick","year":"2019","unstructured":"Warrick\u00a0JI, Sjodahl\u00a0G, Kaag\u00a0M et\u00a0al (2019) Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 75:18\u201322","journal-title":"Eur Urol"},{"key":"688_CR56","first-page":"S100","volume":"40","author":"M Wessolly","year":"2019","unstructured":"Wessolly\u00a0M, Mairinger\u00a0FD, Herold\u00a0T et al (2019) Proteasomale Immunescape-Mechanismen beim Urothelkarzinom. Pathologe 40:S100","journal-title":"Pathologe"},{"key":"688_CR57","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-05-0259","volume":"11","author":"PJ Wild","year":"2005","unstructured":"Wild\u00a0PJ, Herr\u00a0A, Wissmann\u00a0C et\u00a0al (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11:4415\u20134429","journal-title":"Clin Cancer Res"},{"key":"688_CR58","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan\u00a0M, Hopkins\u00a0A, Jaffee\u00a0EM (2017) Tumor mutational burden and response rate to PD\u20111 inhibition. N\u00a0Engl J Med 377:2500\u20132501","journal-title":"N Engl J Med"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-019-00688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-019-00688-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-019-00688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T01:04:42Z","timestamp":1604711082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-019-00688-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":58,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s00292-019-00688-5","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"8 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Reis: Honorare von Roche und Bristol-Myers Squibb; Forschungsunterst\u00fctzung von Bristol-Myers Squibb; Aufwandsentsch\u00e4digung von Philips. T.\u00a0Szarvas: Honorare von Sando.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}